262 related articles for article (PubMed ID: 30848386)
21. Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis.
Ono S; Saito T; Terui K; Yoshida H; Enomoto H
Genesis; 2019 Oct; 57(10):e23323. PubMed ID: 31218818
[TBL] [Abstract][Full Text] [Related]
22. Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines.
Redden RA; Iyer R; Brodeur GM; Doolin EJ
In Vitro Cell Dev Biol Anim; 2014 Mar; 50(3):188-93. PubMed ID: 24477561
[TBL] [Abstract][Full Text] [Related]
23. Shc family expression in neuroblastoma: high expression of shcC is associated with a poor prognosis in advanced neuroblastoma.
Terui E; Matsunaga T; Yoshida H; Kouchi K; Kuroda H; Hishiki T; Saito T; Yamada S; Shirasawa H; Ohnuma N
Clin Cancer Res; 2005 May; 11(9):3280-7. PubMed ID: 15867224
[TBL] [Abstract][Full Text] [Related]
24. The RUNX Family Defines Trk Phenotype and Aggressiveness of Human Neuroblastoma through Regulation of p53 and MYCN.
Ando K; Nakagawara A
Cells; 2023 Feb; 12(4):. PubMed ID: 36831211
[TBL] [Abstract][Full Text] [Related]
25. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
[TBL] [Abstract][Full Text] [Related]
26. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
[TBL] [Abstract][Full Text] [Related]
27. ALK pERKs up MYCN in neuroblastoma.
Lindner S; Henssen A; Astrahantseff K; Schulte JH
Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
[TBL] [Abstract][Full Text] [Related]
28. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis.
Kogner P; Barbany G; Dominici C; Castello MA; Raschellá G; Persson H
Cancer Res; 1993 May; 53(9):2044-50. PubMed ID: 8481906
[TBL] [Abstract][Full Text] [Related]
30. Signal transduction pathways through TRK-A and TRK-B receptors in human neuroblastoma cells.
Sugimoto T; Kuroda H; Horii Y; Moritake H; Tanaka T; Hattori S
Jpn J Cancer Res; 2001 Feb; 92(2):152-60. PubMed ID: 11223544
[TBL] [Abstract][Full Text] [Related]
31. 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma.
Siaw JT; Javanmardi N; Van den Eynden J; Lind DE; Fransson S; Martinez-Monleon A; Djos A; Sjöberg RM; Östensson M; Carén H; Trøen G; Beiske K; Berbegall AP; Noguera R; Lai WY; Kogner P; Palmer RH; Hallberg B; Martinsson T
Cell Rep; 2020 Sep; 32(12):108171. PubMed ID: 32966799
[TBL] [Abstract][Full Text] [Related]
32. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
33. The influence of biologic factors on the surgical decision in advanced neuroblastoma.
Hsu WM; Jen YM; Lee H; Kuo ML; Tsao PN; Chen CN; Lai DM; Lin MT; Lai HS; Chen WJ; Hsieh FJ
Ann Surg Oncol; 2006 Feb; 13(2):238-44. PubMed ID: 16418884
[TBL] [Abstract][Full Text] [Related]
34. microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma.
He XY; Tan ZL; Mou Q; Liu FJ; Liu S; Yu CW; Zhu J; Lv LY; Zhang J; Wang S; Bao LM; Peng B; Zhao H; Zou L
Clin Cancer Res; 2017 Jun; 23(11):2905-2918. PubMed ID: 28003306
[No Abstract] [Full Text] [Related]
35. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
[TBL] [Abstract][Full Text] [Related]
36. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
37. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
38. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
Pacenta HL; Macy ME
Drug Des Devel Ther; 2018; 12():3549-3561. PubMed ID: 30425456
[TBL] [Abstract][Full Text] [Related]
39. Emerging importance of ALK in neuroblastoma.
Azarova AM; Gautam G; George RE
Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
[TBL] [Abstract][Full Text] [Related]
40. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
